These are used in the treatment of epilepsy. The arrangement is for the US market for an up-front payment of $10 mn. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of Elepsia XRTM.

SPARC and Sun Pharma enter into a licensing arrangement for Elepsia tablets

Leave a Reply

Your email address will not be published. Required fields are marked *